CLINICAL TRIALS PROFILE FOR DAUNORUBICIN CITRATE
✉ Email this page to a colleague
All Clinical Trials for DAUNORUBICIN CITRATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00427414 ↗ | Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma | Terminated | National Cancer Institute (NCI) | Phase 1 | 2008-09-01 | RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma. |
| NCT00427414 ↗ | Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma | Terminated | The Emmes Company, LLC | Phase 1 | 2008-09-01 | RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma. |
| NCT00427414 ↗ | Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma | Terminated | The EMMES Corporation | Phase 1 | 2008-09-01 | RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma. |
| NCT00427414 ↗ | Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma | Terminated | AIDS Malignancy Consortium | Phase 1 | 2008-09-01 | RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma. |
| NCT00967057 ↗ | Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | Completed | Children's Cancer and Leukaemia Group | Phase 3 | 2002-10-01 | RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia. PURPOSE: This partially randomized phase III trial is studying how well combination chemotherapy works in treating young patients with relapsed or refractory acute lymphoblastic leukemia. |
| NCT03299452 ↗ | Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Unknown status | Alphacait, LLC | Phase 2 | 2017-01-01 | This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DAUNORUBICIN CITRATE
Condition Name
Clinical Trial Locations for DAUNORUBICIN CITRATE
Trials by Country
Clinical Trial Progress for DAUNORUBICIN CITRATE
Clinical Trial Phase
Clinical Trial Sponsors for DAUNORUBICIN CITRATE
Sponsor Name
